Marinomed Biotech AG financials
Marinomed Biotech AG
529900GN3B1EN80XF405 | Line item | 2023 | 2022 |
|---|---|---|
| Income statement | ||
| Revenue | €9.2M | €11.3M |
| Other income | €1.4M | €837.6K |
| Employee benefits expense | €5.0M | €4.8M |
| Raw materials & consumables used | €5.9M | €7.3M |
| Depreciation & amortisation | €678.2K | €669.7K |
| Operating profit (EBIT) | -€5.1M | -€4.9M |
| Net finance income / (cost) | -€1.7M | -€1.5M |
| Finance costs | €2.5M | €2.7M |
| Profit before tax | -€6.8M | -€6.4M |
| Income tax expense | €4.0K | €6.8K |
| Profit for the year | -€6.8M | -€6.4M |
| Total comprehensive income | -€6.8M | -€6.4M |
| Per share | ||
| Basic EPS | €-4500.00 | €-4300.00 |
| Diluted EPS | €-4500.00 | €-4300.00 |
| Cash flow statement | ||
| Net cash from operating activities | -€4.5M | -€5.2M |
| Net cash from investing activities | -€128.5K | -€207.5K |
| Net cash from financing activities | -€929.7K | €7.8M |
| Proceeds from borrowings | €0 | €6.2M |
| Lease liability payments | €7.3K | €16.4K |
| Balance sheet | ||
| Total assets | €14.6M | €22.3M |
| Non-current assets | €7.5M | €8.0M |
| Property, plant & equipment | €5.9M | €6.2M |
| Current assets | €7.1M | €14.3M |
| Inventories | €1.0M | €1.6M |
| Trade & other receivables | €3.5M | €4.5M |
| Cash & equivalents | €2.6M | €8.2M |
| Total equity | -€10.1M | -€4.2M |
| Non-current liabilities | €15.1M | €20.5M |
| Long-term borrowings | €14.8M | €20.2M |
| Current liabilities | €9.7M | €6.0M |
| Current portion of long-term borrowings | €7.0M | €2.4M |
| Derived metrics | ||
| Operating margin | -55.9% | -43.6% |
| Net margin | -74.0% | -56.7% |
| Return on equity | 67.0% | 153.9% |
| Cash conversion ratio | 0.67× | 0.81× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | -€549.7K | €534.7K |
| Adjustments For Decrease Increase In Other Assets | €4.9K | €8.9K |
| Adjustments For Decrease Increase In Trade and Other Receivables | -€995.6K | -€1.5M |
| Adjustments For Depreciation and Amortisation Expense | €678.2K | €669.7K |
| Adjustments For Finance Costs | €2.5M | €2.7M |
| Adjustments For Finance Income | €861.8K | €1.2M |
| Adjustments For Increase Decrease In Trade and Other Payables | -€818.2K | -€1.4M |
| Adjustments To Reconcile Profit Loss Other Than Changes In Working Capital | -€51.4K | -€48.4K |
| Capital Reserve | €44.9M | €44.1M |
| Comprehensive Income Attributable To Owners of Parent | -€6.8M | -€6.4M |
| Current Tax Assets Current | €2.4K | €2.8K |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | €2.5K | €1.4K |
| Equity and Liabilities | €14.6M | €22.3M |
| Finance Costs Paid Classified As Operating Activities | €773.1K | €448.7K |
| Finance Income | €861.8K | €1.2M |
| Finance Income Received Classified As Operating Activities | €10.9K | €0 |
| Income Taxes Paid Refund Classified As Operating Activities | €4.0K | €6.8K |
| Increase Decrease In Cash and Cash Equivalents | -€5.6M | €2.4M |
| Increase Decrease Through Conversion of Convertible Instruments | €817.5K | €2.0M |
| Increase Decrease Through Sharebased Payment Transactions | -€2.1K | €81.2K |
| Intangible Assets Other Than Goodwill | €1.5M | €1.8M |
| Issued Capital | €1.5M | €1.5M |
| Other Current Financial Liabilities | €1.2M | €2.4M |
| Other Expense By Nature | €1.9M | €2.4M |
| Other Noncurrent Nonfinancial Assets | €6.7K | €11.6K |
| Other Noncurrent Payables | €254.7K | €304.9K |
| Proceeds From Issue of Bonds Notes and Debentures | €620.0K | €1.8M |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | €0 | €20.1K |
| Repayments of Noncurrent Borrowings | €1.5M | €200.0K |
| Retained Earnings | -€56.6M | -€49.8M |
| Services Expense | €2.2M | €1.9M |
| Trade and Other Current Payables To Trade Suppliers | €1.5M | €1.2M |
Every line item above is a fact tagged in Marinomed Biotech AG's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.